Trudi Singleton Cloyd, MD

Dr. Nancy Kerner is a physician-scientist who has clinical and research expertise in the intersection of sleep and circadian rhythm disturbances and cognitive impairment, including Alzheimer’s disease and related dementias (ADRD). Her clinical background is in geriatric psychiatry. She is board certified in General Psychiatry and Geriatric Psychiatry. Her clinical practice has focused on healthy aging and late-life neuropsychiatric disorders, encompassing sleep and behavioral disturbances, depression, anxiety, and psychosis in older adults with stroke, Parkinson’s disease, and dementia. Dr. Kerner also received fellowship training in research, supported by a NIH-funded T32 Late-life Neuropsychiatric Disorders research training program, with a focus on studying the association between vascular depression, cognitive impairment, and obstructive sleep apnea (OSA). In recent years, Dr. Kerner has assembled a multi-disciplinary team with renowned research investigators in an older adult population, including (1) Davangere Devanand MD, an expert in geriatric depression and cognitive impairment diagnosis and treatment, (2) Jose Luchsinger MD, MPH, an expert in dementia risk factor research, (3) Terry Goldberg, PhD, an expert in cognitive diagnostic instruments, and (4) sleep and circadian rhythm research experts (e.g., Johns Hopkins University). I have also established a consultant team, including Yaakov Stern, Ph.D., an expert in neuropsychology and cognitive reserve, and Mitchell Elkind, MD, MPH, an expert in cerebrovascular disease associated with cognitive impairment and dementia. Her projects include implementing early screening and diagnosing cognitive decline and sleep/circadian rhythm disturbance in clinical and community settings. Dr. Kerner’s optimal goal is to develop a novel diagnostic matrix and treatment for sleep and circadian rhythm disturbances among older adults with cognitive concerns, MCI, and dementia in order to optimize their quality of life and improve long-term cognitive outcomes.

Dr. Sharon Newman-Meininger is an Assistant Professor of Pediatrics in Emergency Medicine at the Columbia University Medical Center. Dr. Newman is a board-certified pediatrician and an attending pediatrician in the Department of Emergency Medicine at the NewYork Presbyterian Morgan Stanley Children's Hospital. Dr. Newman is a graduate of the MD/PhD program, Columbia University College of Physicians and Surgeons, and completed her Pediatric Residency at the Mount Sinai Hospital.

Scott E. Brodie, MD, Ph.D., is a Professor of Clinical Ophthalmology and Attending Ophthalmologist in the Department of Ophthalmology. He is an internationally known clinician-scientist, and a leader in the use of electrophysiologic techniques for diagnosing of visual impairments in children and adults.Dr. Brodie is a graduate of the combined MD-PhD program at Weill-Cornell Medical College and The Rockefeller University in New York. He completed his PhD in retinal physiology in the laboratory of Nobel Laureate H. K. Hartline, under the supervision of Dr. Floyd Ratliff and Prof. Bruce Knight. He completed a medical internship and residency training in ophthalmology at The New York Hospital, and subsequently received fellowship training in medical retinal disorders and clinical electrophysiology of vision at New York University and Bellevue Hospital under the supervision of Dr. Ronald Carr, with support as a John Kluge Fellow of the Retinitis Pigmentosa Foundation.He is a fellow of the American Academy of Ophthalmology, and a fellow of the Association for Research in Vision and Ophthalmology. He is a member of the International Society for Clinical Electrophysiology of Vision, the International Society for Genetic Eye Disease, and the Ophthalmic Genetics Study Club. Dr. Brodie has been honored with the Senior Achievement Award of the American Academy of Ophthalmology, as well as the Academy's Secretariat Award for Education.Dr. Brodie’s research centers on improving methodologies for electrophysiologic testing, and descriptions of novel findings in patients with inherited and metabolic retinal disorders. He has been a key member of the teams which have introduced important new therapies, including enzyme-replacement therapy for Fabry disease, and intra-arterial chemotherapy for retinoblastoma, which has increased the rate of salvage of diseased eyes in the most severely affected patients from 20% to over 90%.Dr. Brodie has published extensively on electrophysiology and retinal disorders. He has a particular interest in clinical optics, and has served as Chair of the Editorial committee for the American Academy of Ophthalmology’s Basic and Clinical Science Course on Clinical Optics for the past ten years. In his spare time, he enjoys reading mathematics, and playing the oboe in local orchestras and chamber groups.